News Quantified

ANRO – alto neuroscience, inc. (US:NASDAQ)

Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]

4/21

08:53 am

anro

Medium

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]

Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.

Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}